Physician
Oncology
Dr. Stephen Frytak, MD
|
|
Give Review
Stephen Frytak, MD is an expert in the field of Oncology. He went to Jefferson Medical College. Stephen Frytak is also a published physician. He has 100 publication published. The most recent publication is: A phase I study of cytembena.
Publications
- Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.
- Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin...
- Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs.
- Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management.
- Phase II trial of gemcitabine in advanced sarcomas.
- Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer.
- Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
- Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy.
- Cerebral toxicity in patients treated for small cell carcinoma of the lung.
- Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
- The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
- Mitomycin lung toxicity. Acute and chronic phases.
- Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis.
- The case of the phantom bladder.
- Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung ...
- Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer.
- Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma ...
- Role of radiation therapy in the management of lung cancer.
- Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
- Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy.
- Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease.
- Prophylactic cranial irradiation in limited-stage small cell lung cancer.
- Management of nausea and vomiting in the cancer patient.
- Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorour...
- Phase II study of maytansine in advanced breast cancer.
- Phase II evaluation of PALA in patients with metastatic lung cancer.
- Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy.
- Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
- Concomitant radiation therapy and cis-diamminedichloroplatinum (II) in patients with advanced head and neck cancer.
- Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of t...
- A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on th...
- Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in...
- Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
- A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer.
- Phase II evaluation of AMSA in patients with metastatic lung cancer.
- Phase I study of diaziquone.
- Phase II study of diaziquone in patients with advanced carcinoma of the lung.
- Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
- A controlled clinical and immunological evaluation of immunotherapy with Bacillus Calmette--Guerin in patients with metastatic cancer.
- Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
- Phase II study on DON in patients with previously treated advanced lung cancer.
- Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer.
- Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
- An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer.
- A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer.
- Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
- Phase II evaluation of triazinate in patients with metastatic lung cancer.
- Is THC an effective antiemetic for cancer patients? Opinion 1.
- Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.
- Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.
- Magnetic resonance imaging for neurotoxicity in long-term survivors of carcinoma.
- Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma.
- Phase II trial of diaziquone in malignant mesothelioma.
- Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients.
- Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP.
- Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
- Necrotic lung and bronchopleural fistula as complications of therapy in lung cancer.
- A phase I clinical trial of recombinant human tumor necrosis factor.
- Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.
- Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.
- Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomas.
- Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
- Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.
- Delayed leukoencephalopathy in survivors with small cell lung cancer.
- No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer.
- Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. A preliminary report.
- Continuous five-drug versus alternating three-drug and two-drug chemotherapy after five-drug or three-drug induction in extensive small cell lung cancer.
- Treatment toxicities in long-term survivors of limited small cell lung cancer.
- Treatment of "limited" stage III non-small cell carcinoma of the lung.
- A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic n...
- Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
- Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung.
- Cytogenetic studies in 11 patients with small cell carcinoma of the lung.
- Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation.
- Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
- Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.
- A technetium-labeled monoclonal antibody for imaging metastatic melanoma.
- Phase II evaluation of menogaril in patients with advanced hypernephroma.
- Life-threatening bleomycin pulmonary toxicity with ultimate reversibility.
- A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer.
- Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer.
- Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
- Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
- A phase I study of cytembena.
- Phase II study of pyrazofurin in advanced colorectal carcinoma.
- Phase II studies of polychemotherapy regimens in small cell lung cancer.
- Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
- Phase II evaluation of maytansine in patients with metastatic lung cancer.
- Surgically proven pulmonary metastases not demonstrated by computed chest tomography.
- cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosph...
- VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
- Neurologic toxicity associated with high-dose metronidazole therapy.
- Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.
- Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
- Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
- Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
- Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
- VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung.
- Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG.
Schools
Thomas Jefferson University
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
Education
-
Mayo School of Graduate Medical Education -
Jefferson Medical College
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Janell N. Shaw, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saravut J. Weroha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Erlichman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randolph S. Marks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prashant Kapoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald L. Richardson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prema P. Peethambaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew P. Goetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert C. Miller, MD |
|
|
Dr. Robert B. Diasio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pashtoon M. Kasi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katharine A. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evanthia Galanis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreas S. Beutler, MD
This Doctor is OpenDoctor Recommended.
|